OPC 12759

PURPOSE To investigate the efficacy and safety of 2% rebamipide ophthalmic suspension administered 4 times daily for 52 weeks in… Expand

OBJECTIVE To investigate the efficacy of 2% rebamipide ophthalmic suspension compared with 0.1% sodium hyaluronate ophthalmic… Expand

OBJECTIVE To investigate the dose response for efficacy of 1% and 2% rebamipide ophthalmic suspension compared with placebo in… Expand

The purpose of the study was to determine if OPC-12759 stimulates secretion from conjunctival goblet cells in culture and if it… Expand

PURPOSE To determine if the gastroprotective drug OPC-12759 increased proliferation of rat conjunctival goblet cells in culture… Expand

Rebamipide (OPC-12759), a quinolone derivative, and OPC-6535, a thiazol-carboxylic acid derivative, are compounds with ability to… Expand

The effect of rebamipide (2-(4-chlorobenzoylamino)-3-[2 (1H)-quinolinon-4-yl]-propionic acid, OPC-12759, CAS 11911-87-6), an anti… Expand

The protective effect of rebamipide against 0.15 N HCl solution containing 40% ethanol (HCl-ethanol)-induced mucosal lesion in… Expand

The antiulcer effects of OPC-12759, a novel antiulcer agent were compared with those of cetraxate in various experimental ulcer… Expand

OPC-12759, 2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl]-propionic acid, was studied for its efficacy to prevent the gastric… Expand